Targeted deletion of A2A adenosine receptors attenuates the protective effects of myocardial postconditioning

R Ray Morrison1, Xing Lin Tan, Catherine Ledent

  • 1Div. of Critical Care Medicine, St. Jude Children's Research Hospital, 332 N. Lauderdale St., MS 734, Memphis, TN 38105, USA. ray.morrison@stjude.org

Insights

Endogenous adenosine A(2A) receptors are essential for the cardioprotective effects of postconditioning (POC). Blocking these receptors or deleting the A(2A) receptor gene prevents POC-induced heart protection.

Area of Science:

  • Cardiovascular Physiology
  • Molecular Cardiology
  • Pharmacology

Background:

  • Endogenous adenosine mediates cardioprotection via postconditioning (POC).
  • The specific adenosine receptor subtype responsible for POC-induced protection remains unclear.
  • A(2A) adenosine receptors are implicated in various protective signaling pathways.

Purpose of the Study:

  • To investigate the critical role of A(2A) adenosine receptors in mediating the cardioprotective effects of POC.
  • To determine if A(2A) receptor antagonism or genetic deletion abrogates POC-induced myocardial protection.

Main Methods:

  • Global ischemia-reperfusion in isolated wild-type (WT) and A(2A) adenosine receptor knockout (A(2A)KO) mouse hearts.
  • Assessment of postischemic functional recovery and cardiac troponin I (cTnI) release.
  • Evaluation of Akt and extracellular signal-regulated kinase (ERK) 1/2 phosphorylation as markers of protective signaling.

Main Results:

  • POC significantly improved functional recovery and reduced cTnI release in WT hearts.
  • These protective effects were abolished by A(2A) receptor antagonist ZM-241385 and in A(2A)KO hearts.
  • POC failed to enhance Akt and ERK1/2 phosphorylation in A(2A)KO hearts or with A(2A) receptor blockade.

Conclusions:

  • Endogenous activation of A(2A) adenosine receptors is a crucial trigger for the cardioprotective effects of POC.
  • A(2A) adenosine receptors are essential for mediating postconditioning-induced myocardial protection in murine hearts.

Related Concept Videos

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers01:24

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which indirectly block calcium...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Adrenergic Receptors: ɑ Subtype01:31

Adrenergic Receptors: ɑ Subtype

Adrenoceptors are classified into α and ꞵ classes based on their potencies to catecholamine agonists. α-adrenoceptors show the following order of catecholamine potency:
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase C—inositol-1,4,5-trisphosphate...